Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G-CSF based regimens

MeSH terms

• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Core Binding Factors
• Cytarabine* / therapeutic use
• Granulocyte Colony-Stimulating Factor / therapeutic use
• Humans
• Leukemia, Myeloid, Acute* / drug therapy
• Leukemia, Myeloid, Acute* / genetics
• Mutation
• Vidarabine / therapeutic use